Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Atypical or second-generation antipsychotic indicated for the treatment of schizophrenia and other psychotic disorders. Oral administration in two to three daily doses.
Since the last update, we have not found any published data on its excretion in breastmilk.
The little pharmacokinetic data that is known makes it difficult to predict its excretion in breastmilk.
It has very few and/or very old bibliographic references and is sold in very few countries for reasons of efficacy and efficiency compared to other antipsychotics. (Carpenter 2004)
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in cases of prematurity.
See below the information of this related product: